secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001104659-25-107419
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise Q3 net loss $40.7M ($0.39/sh); cash $563.3M; GRAND CANYON data Q4 2026
-------------------------------------------------------------------------------

- Cash, equivalents and marketable securities $563.3M at Sep 30, 2025.
- R&D expense $37.5M (up $3.9M QoQ) driven by EDG-15400 Phase 1 start and CIRRUS-HCM activity.
- Net loss $40.7M ($0.39 per share) vs $36.1M ($0.34) prior quarter.
- GRAND CANYON pivotal Becker cohort (175 enrolled) on track for topline readout in Q4 2026.
- EDG-7500 CIRRUS-HCM program update expected Q4 2025; EDG-15400 Phase 1 data H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000110465925107419/0001104659-25-107419-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000110465925107419/tm2529979d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-107419

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer